Results 141 to 150 of about 30,495,821 (312)

Data for: Panel Data Models and the Uncovered Interest Parity Condition: The Role of Two-Way Unobserved Components

open access: yes, 2018
Eviews file containing the data and replicating the results of: Herger, Nils (2016), ‘Panel Data Models and the Uncovered Interest Parity Condition: The Role of Two-Way Unobserved Components’, International Journal of Finance and Economics 21, 294 ...
Herger, N (via Mendeley Data)   +2 more
core   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim   +17 more
wiley   +1 more source

On the robustness of fixed effects and related estimators in correlated random coefficient panel data models. [PDF]

open access: yes
I show that a class of fixed effects estimators is reasonably robust for estimating the population-averaged slope coefficients in panel data models with individual-specific slopes, where the slopes are allowed to be correlated with the covariates.
Jeffrey M. Wooldridge
core  

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

open access: yesMolecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim   +11 more
wiley   +1 more source

Hospitals universitários: indicadores de utilização e análise de eficiência

open access: yesEconomia Aplicada, 2002
This paper studies the performance of 45 Brazilian federal teaching hospitals, within five semesters as from 1998 by connecting and assessing technical efficiency scores and service indicators.
Alexandre Marinho   +1 more
doaj  

Multiple Time-Serie3 Models Applied to Panel Data [PDF]

open access: yes
This study presents a general methodology for fitting multiple time series models to panel data. The basic statistical framework considered here consists of a dynamic simultaneous equation model where disturbances follow a permanent-transitory scheme ...
Thomas E. MaCurdy
core  

Panel Data Discrete Choice Models of Consumer Deamnd

open access: yes, 2015
18.1. Introduction .................................................................................................................. ...........................................................
Badi H. Baltagi, Michael Keane, Keane, M
core   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba   +5 more
wiley   +1 more source

Estimation of Discrete Time Duration Models with Grouped Data [PDF]

open access: yes
Dynamic discrete choice panel data models have received a great deal of attention. In those models, the dynamics is usually handled by including the lagged outcome as an explanatory variable.
Bo E. Honoré, Luojia Hu
core  

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy